AI assistant
Dechra Pharmaceuticals PLC — Share Issue/Capital Change 2018
Jun 4, 2018
4797_rns_2018-06-04_2f460851-9cbd-4b4c-9db6-7065783878ba.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1966Q
Dechra Pharmaceuticals PLC
04 June 2018
04 June 2018
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 71,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List.
These Shares are being reserved under a block listing and will be issued pursuant to the following scheme:
Scheme Shares
Unapproved Share Scheme 36,000
Long Term Incentive Plan (LTIP) 35,000
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 5 June 2018.
For further information
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: [email protected]
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
ALSUGUAGQUPRGUC